公开(公告)号：DE69724422D1

公开(公告)日：2003-10-02

申请号：DE69724422

申请日：1997-05-12

Applicant: MONASH UNIVERSITY CLAYTON

Inventor： JARROTT BEVYN ,  BEART MARK ,  JACKSON ROY ,  KENCHE BHASKAR ,  ROBERTSON DUNCAN ,  COLLIS PATRICIA

IPC: C07D295/04 ,  A61K31/00 ,  A61K31/34 ,  A61K31/343 ,  A61K31/357 ,  A61K31/495 ,  A61K31/496 ,  A61P9/00 ,  A61P25/04 ,  A61P25/18 ,  A61P39/00 ,  A61P39/06 ,  A61P43/00 ,  C07D209/12 ,  C07D213/30 ,  C07D213/38 ,  C07D295/08 ,  C07D295/084 ,  C07D295/18 ,  C07D295/185 ,  C07D307/81 ,  C07D311/58 ,  C07D311/72 ,  C07D317/58 ,  C07D333/28 ,  C07D333/54 ,  C07D405/12 ,  C07D409/12 ,  C07D209/14 ,  C07D295/096 ,  C07D295/192 ,  C07D311/66

Abstract: Arylalkylpiperazine compounds (1) wherein B is aryl or optionally substituted aryl; R1 is hydroxy; R2 and R3 are the same or different and are independently selected from hydrogen or C1-3 alkyl; m is 0, 1 or 2; D is a linking chain of atoms which may be optionally substituted and which contains from 1 to 8 atoms in the chain; E is a phenolic antioxidant group or a corresponding amino derivative thereof wherein the phenolic hydroxyl is replaced by amino, are disclosed. The compounds have both free radical scavenging activity and block excitatory amino acid activity. Some compounds of the present invention also display an affinity for voltage-sensitive sodium channels.

公开(公告)号：AU2003901149A0

公开(公告)日：2003-03-27

申请号：AU2003901149

申请日：2003-03-13

Applicant: MONASH UNIVERSITY SCHOOL OF PH

IPC: C09D5/08 ,  C23F11/08

公开(公告)号：DE69430479T2

公开(公告)日：2002-11-28

申请号：DE69430479

申请日：1994-07-28

Applicant: MONASH UNIVERSITY CLAYTON

Inventor： GANI SUSAN ,  WIRTH HANS-JURGEN ,  AGUILAR ISABEL ,  HEARN THOMAS ,  VANSELOW GEORGE ,  CHEANG HONG ,  ERIKSSON KJELL-OVE

IPC: B01J20/281 ,  B01J20/06 ,  B01J20/32 ,  C01G25/02 ,  C02F1/28 ,  C04B35/14 ,  C04B35/48 ,  C04B35/626 ,  C04B38/00 ,  C04B38/08 ,  C12N11/14 ,  G01N30/88 ,  G01N33/551 ,  C04B35/482 ,  G01N30/48

Abstract: Porous zirconia or zirconium-containing particles, methods of making such particles and methods of using such particles including modifications to the surface of the particles are described. The method comprises heating zirconia particles to provide a substantially homogeneously liquid melt, quenching the particles of melt to effect spinodal decomposition to provide quench particles of a silica rich phase and a zirconia rich phase, annealing the quenched particles to provide non porous solid particles of zirconia and silica and, leaching the silica from these particles to produce porous solid zirconia particles comprising a three dimensionally substantially continuous interpenetrating network of interconnected pores.

公开(公告)号：DE3856387T2

公开(公告)日：2000-05-11

申请号：DE3856387

申请日：1988-03-31

Applicant: MONASH UNIVERSITY CLAYTON ,  POLYCHIP ELECTRONICS PTY LTD

Inventor： COPP FREDERICK ,  BOURA ALAN ,  JACKSON WILLIAM ,  CULLEN JOHN

IPC: A61K31/55 ,  A61P1/08 ,  A61P1/12 ,  A61P3/00 ,  A61P9/00 ,  A61P9/12 ,  A61P11/00 ,  A61P25/00 ,  A61P25/24 ,  A61P25/26 ,  A61P37/08 ,  A61P43/00 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04

Abstract: PCT No. PCT/AU88/00095 Sec. 371 Date Dec. 7, 1989 Sec. 102(e) Date Dec. 7, 1989 PCT Filed Mar. 31, 1988 PCT Pub. No. WO88/07997 PCT Pub. Date Oct. 20, 1988. (I) (II) A compound of general formula (I), wherein X=CH2, O, S or NR4, and Y=formula (II): where R1=H, lower alkyl or an aryloxyalkyl group, wherein the aryl group is optionally substituted by alkyl, alkoxy, hydrogen, alkyl substituted by hydrogen, and n is an integer between 0 and 5, and Z=O, S or NR2; wherein R2=H, lower alkyl, hydroxy, amino cyano or acyl, R3=H, or lower alkyl, and R4=H, lower alkyl, or lower acyl, and pharmaceutically acceptable salts thereof.

公开(公告)号：DE2901721C2

公开(公告)日：1986-06-19

申请号：DE2901721

申请日：1979-01-17

Applicant: MONASH UNIVERSITY, CLAYTON, VICTORIA, AU

Inventor： POTTER, OWEN EDWARD, CAMBERWELL, VICTORIA, AU

IPC: F26B3/00 ,  F26B3/08 ,  F26B3/084 ,  F26B3/10 ,  F26B23/00 ,  F26B23/10

公开(公告)号：US20250122631A1

公开(公告)日：2025-04-17

申请号：US18567599

申请日：2022-05-25

Applicant: MONASH UNIVERSITY

Inventor： Douglas R. MACFARLANE ,  Alexandr Nikolaevich SIMONOV ,  Hoang-Long DU

IPC: C25B1/27 ,  C25B1/50 ,  C25B9/17 ,  C25B9/19

Abstract: The invention provides a method of reducing dinitrogen to produce ammonia, the method comprising: contacting a cathode of an electrochemical cell with an electrolyte comprising: (i) a metal cation selected from the group consisting of lithium, magnesium, calcium, strontium, barium, zinc, aluminium, vanadium and combinations thereof, wherein the metal cation is present at a concentration of greater than 0.5 mol/L in the electrolyte, (ii) one or more anions comprising at least one negative ion selected from the group consisting of fluorinated sulfonyl imides, fluorinated sulfonyl methides and combinations thereof, (iii) a proton carrier; and (iv) optionally, at least one phosphonium cation, wherein the combined amount of the metal cation and the optional at least one phosphonium cation is greater than 1 mol/L in the electrolyte; supplying dinitrogen to the electrochemical cell for cathodic reduction; and applying a potential at the cathode sufficient to reduce the dinitrogen, thereby producing ammonia.

公开(公告)号：US20250108018A1

公开(公告)日：2025-04-03

申请号：US18930615

申请日：2024-10-29

Applicant: Monash University

Inventor： Johanna Elisabeth FRASER ,  David Andrew JANS ,  Kylie Michelle WAGSTAFF

IPC: A61K31/167 ,  A61K31/203

Abstract: This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV.

公开(公告)号：US20250034222A1

公开(公告)日：2025-01-30

申请号：US18717170

申请日：2022-12-07

Applicant: Monash University ,  HUdson Institute of Medical Research

Inventor： Claudia Annelie Nold ,  Andrew Malcolm Ellisdon ,  Marcel Friedrich Nold ,  James Whisstock

IPC: C07K14/54 ,  A61K38/00 ,  A61P29/00 ,  A61P37/06 ,  C12N15/70

Abstract: This invention relates to polypeptides, including variants of interleukin-38 (IL-38), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric polypeptide comprising an amino acid sequence of an IL-38 monomer, the amino acid sequence having a mutation or modification for preventing the peptide from forming a homodimer and favouring the formation of a stable monomer.

公开(公告)号：US20240382588A1

公开(公告)日：2024-11-21

申请号：US18693109

申请日：2022-09-21

Applicant: MONASH UNIVERSITY

Inventor： Joshua Daniel OOI ,  Peter James EGGENHUIZEN ,  Eric MORAND

IPC: A61K39/00 ,  A61P37/06 ,  C07K14/725 ,  C12N5/0783

Abstract: The present invention relates to methods and compositions for treating autoimmune or inflammatory disease characterised by an aberrant or inappropriate immune response to one or more of Ro60 protein; MPO protein; and Smith protein.

公开(公告)号：US20240358652A1

公开(公告)日：2024-10-31

申请号：US18291808

申请日：2022-08-17

Applicant: Monash University

Inventor： Hareth Basim Ali AL-WASSITI ,  Colin William POUTON ,  Kha Tu Joan HO

IPC: A61K9/51 ,  A61K31/713 ,  A61K39/00 ,  A61K48/00 ,  A61P37/08

CPC classification number: A61K9/5146 ,  A61K9/5123 ,  A61K31/713 ,  A61K39/0005 ,  A61K48/0041 ,  A61P37/08 ,  A61K2039/53 ,  A61K2039/55555 ,  A61K2039/572

Abstract: The present invention is directed to lipid nanoparticles, formulations containing lipid nanoparticles and methods of treating diseases or conditions with said lipid nanoparticles and formulations thereof. A lipid nanoparticle comprising (a) an active agent; (b) a cationic and/or ionisable lipid comprising from about 40 mol % to about 60 mol % of the total lipid present in the nanoparticle; (c) a phospholipid comprising from about 5 mol % to about 20 mol % of the total lipid present in the nanoparticle; (d) a structural lipid comprising from about 30 mol % to about 50 mol % of the total lipid present in the nanoparticle; (e) a PEGylated lipid comprising from about 0.05 mol % to less than 0.5 mol % of the total lipid present in the nanoparticle.